A Phase 2 study evaluating sabizabulin + enobosarm combination therapy in patients with metastatic triple negative breast cancer after two systemic chemotherapies
Latest Information Update: 03 Dec 2021
At a glance
- Drugs Enobosarm (Primary) ; Sabizabulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 03 Dec 2021 New trial record
- 02 Dec 2021 According to a Veru media release, this study is expected to begin Q1 2022.